ClinicalTrials.gg
Not yet recruitingNCT07769203Updated Aug 17, 2026

Effects of MET and MFR on Piriformis Syndrome

An interventional study of Muscle Energy Technique and Myofascial Release Technique in Piriformis Syndrome, sponsored by Igdir University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Igdir University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of this study is to comparatively evaluate the effects of two different manual therapy approaches, Muscle Energy Technique (MET) and Myofascial Release Technique (MFR), on pain threshold, muscle activation patterns, and muscle strength in individuals diagnosed with piriformis syndrome.

In this study, the physiological effects of both interventions on the musculoskeletal system will be assessed using objective measurement tools such as an algometer, digital dynamometer, and electromyography (EMG). The study aims to provide evidence-based data regarding the most effective and preferable manual therapy approach in the conservative treatment of piriformis syndrome.

Read the detailed description

Participants included in the study will complete the Sociodemographic Information Form, Oswestry Disability Index (ODI), Lower Extremity Functional Scale (LEFS), World Health Organization Quality of Life Scale Brief Form (WHOQOL-BREF), Pittsburgh Sleep Quality Index (PSQI), and the Short-Form McGill Pain Questionnaire (SF-MPQ).

Additionally, participants will undergo the 6-Minute Walk Test (6MWT). Lower extremity muscle strength will be evaluated using a digital dynamometer, pain threshold will be assessed with an algometer, and muscle activation patterns will be evaluated using surface electromyography (sEMG) in the FAIR position.

The entire assessment procedure will take approximately 30-40 minutes, and all measurements will be performed under standardized conditions by the same researcher.

This study is a randomized controlled experimental trial aiming to compare the effects of two different manual therapy approaches, Muscle Energy Technique (MET) and Myofascial Release Technique (MFR), on pain threshold, muscle activation patterns, and muscle strength in individuals diagnosed with piriformis syndrome.

The study is designed as a pretest-posttest trial. Participants will be randomly allocated into three groups: the MET group, the MFR group, and the control group. All groups will receive treatment for 8 weeks, with 2 sessions per week, totaling 16 treatment sessions.

02

Conditions studied

  • Piriformis Syndrome

Keywords

  • Piriformis Syndrome
  • Muscle Energy Technique
  • Myofascial Release
  • Surface EMG
  • Pain Threshold
  • Muscle Strength
  • Rehabilitation
03

In context

Piriformis Muscle Syndrome

58 studies on the registry are indexed under Piriformis Muscle Syndrome; 23 are open to participants now.

This study's planned enrollment of 72 is above the median of 42 across 52 interventional studies indexed under Piriformis Muscle Syndrome.

Browse Piriformis Muscle Syndrome studies →

Lead sponsor

Igdir University is the lead sponsor of 18 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals diagnosed with piriformis syndrome
  • Presence of piriformis tenderness and sciatic symptoms
  • Aged between 18 and 65 years
  • Voluntary agreement to participate in the study
  • No history of lumbar, hip, knee, or ankle surgery within the last year
  • Ability to cooperate with the assessment and treatment procedures

Exclusion criteria

Exclusion Criteria:

  • Individuals younger than 18 years or older than 65 years
  • Presence of any musculoskeletal disorder affecting the lower extremity
  • Presence of neurological, cardiac, pulmonary, or orthopedic disorders preventing participation in exercise
  • Presence of neurological deficits (muscle strength loss)
  • History of radiotherapy to the lumbar or hip region
  • Absence from more than 20% of treatment sessions
  • Inability to comply with the study procedures (e.g., cognitive impairment, communication problems, severe psychiatric disorders)
  • or PRP injection within the last 3 months
  • Participation in another physical therapy program within the last 3 months
  • Use of analgesic, anti-inflammatory, or muscle relaxant medications within the last 48-72 hours
  • Use of psychotropic medications that may affect muscle activation or nervous system responses (e.g., antidepressants, antipsychotics, sedatives)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Muscle Energy Technique Group

    Participants in this group will receive Muscle Energy Technique (MET) in addition to conventional physical therapy for 8 weeks, 2 sessions per week, totaling 16 sessions.

    Procedure: Muscle Energy Technique

  • Experimental
    Myofascial Release Technique Group

    Participants in this group will receive Myofascial Release Technique (MFR) in addition to conventional physical therapy for 8 weeks, 2 sessions per week, totaling 16 sessions.

    Procedure: Myofascial Release Technique

  • Active comparator
    Conventional Physical Therapy Group

    Participants in this group will receive conventional physical therapy for 8 weeks, 2 sessions per week, totaling 16 sessions.

    Procedure: Conventional Physical Therapy

Interventions

  • ProcedureMuscle Energy Technique

    Muscle Energy Technique (MET) will be applied to participants by a trained physiotherapist in addition to conventional physical therapy. The intervention will be performed for 8 weeks, 2 sessions per week, totaling 16 sessions. The technique will include voluntary muscle contractions followed by relaxation and stretching procedures targeting the piriformis muscle.

  • ProcedureMyofascial Release Technique

    Myofascial Release Technique (MFR) will be applied to participants by a trained physiotherapist in addition to conventional physical therapy. The intervention will be performed for 8 weeks, 2 sessions per week, totaling 16 sessions. The technique will involve sustained manual pressure and soft tissue release techniques targeting the piriformis muscle and surrounding fascia.

  • ProcedureConventional Physical Therapy

    Participants in the control group will receive conventional physical therapy for 8 weeks, 2 sessions per week, totaling 16 sessions.

06

What researchers measure

Primary outcomes

  1. Pressure Pain Threshold

    Assessment of pressure pain threshold using an algometer.

    Time frame: Baseline and after 8 weeks of treatment

Secondary outcomes

  1. Pain Severity (SF-MPQ)

    Pain intensity and pain characteristics will be evaluated using the Short-Form McGill Pain Questionnaire (SF-MPQ). Higher scores indicate greater pain severity.

    Time frame: Baseline and after 8 weeks of treatment

  2. Muscle Strength

    Assessment of lower extremity muscle strength using a digital dynamometer.

    Time frame: Baseline and after 8 weeks of treatment

  3. Muscle Activation Pattern

    Assessment of muscle activation patterns using surface electromyography (sEMG) in the FAIR position.

    Time frame: Baseline and after 8 weeks of treatment

  4. Lower Extremity Functional Scale (LEFS)

    Assessment of lower extremity functional status using the Lower Extremity Functional Scale (LEFS).

    Time frame: Baseline and after 8 weeks of treatment

  5. Oswestry Disability Index (ODI)

    Assessment of disability level using the Oswestry Disability Index (ODI).

    Time frame: Baseline and after 8 weeks of treatment

  6. World Health Organization Quality of Life Scale Brief Form (WHOQOL-BREF)

    Assessment of quality of life using the World Health Organization Quality of Life Scale Brief Form (WHOQOL-BREF).

    Time frame: Baseline and after 8 weeks of treatment

  7. Sleep Quality (PSQI)

    Assessment of sleep quality using the Pittsburgh Sleep Quality Index (PSQI).

    Time frame: Baseline and after 8 weeks of treatment

  8. 6-Minute Walk Test

    Assessment of functional exercise capacity using the 6-Minute Walk Test (6MWT).

    Time frame: Baseline and after 8 weeks of treatment

07

Study locations

1 site
  • Hasan Kalyoncu University Faculty of Health Sciences
    Gaziantep, Şehitkamil 27000, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) sharing has not yet been determined. Data sharing plans may be evaluated after study completion in accordance with institutional policies and participant confidentiality.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Nov 2026, 3 months later.

Of 38 non-industry interventional studies with no phase under Piriformis Muscle Syndrome, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 12. This study's planned 3 months is below that.

Counting every sponsor, half of 38 studies reached it within 6 months; a quarter within 4 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2026
First posted
Aug 17, 2026
StartEst.
Aug 30, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07769203
Lead sponsor
Igdir University
Responsible party
Nuran Akdag (Lecturer, PhD Candidate, Igdir University) — Principal investigator
First posted
Aug 17, 2026
Start date
Aug 30, 2026 (estimated)
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Aug 17, 2026

Study contacts

Nuran Akdağ Mirzaoğlu, Msc/PT/Lecture
Contact
ptnurank@gmail.com
+905058179557
Yavuz Yakut, Prof. Dr.
Contact
yavuz.yakut@hku.edu.tr
+905324181001
Yavuz Yakut, Prof. Dr.
principal investigator · Hasan Kalyoncu University Faculty of Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion